Findex Inc
Findex Inc is a Japanese company specializing in healthcare equipment, providing diagnostic and monitoring solutions for medical institutions.
Business. Findex Inc is a healthcare company specializing in advanced medical equipment and technology, primarily engaged in the sale of healthcare equipment. The firm is headquartered in Japan and is listed on the Tokyo Stock Exchange under the ticker symbol 3649.T. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Findex Inc is a healthcare company specializing in advanced medical equipment and technology, primarily engaged in the sale of healthcare equipment. The firm is headquartered in Japan and is listed on the Tokyo Stock Exchange under the ticker symbol 3649.T. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.
Findex Inc maintains a strong liquidity position, with cash and equivalents amounting to ¥2.896 billion, representing 44.2% of total assets. The company operates with no long-term debt, resulting in a debt-to-equity ratio of 0.0 and a current ratio of 5.94, indicating robust short-term financial health. The price-to-book ratio of 3.53 and price-to-tangible-book ratio of 3.53 suggest that the market values the company at a premium to its book value.
In terms of profitability, Findex Inc reports a return on equity (ROE) of 12.23% and a return on assets (ROA) of 9.83%, both exceeding the typical thresholds for the healthcare equipment industry. The company's operating margin of 40.6% (calculated from operating income of ¥862.1 million on revenue of ¥2.125 billion) is significantly higher than the industry median, indicating efficient cost management and strong pricing power.
Geographically, Findex Inc's revenue is primarily concentrated in Japan, with no disclosed international segments. The company's business is not diversified across multiple product lines, as it focuses on healthcare equipment, particularly diagnostic and monitoring solutions. This concentration may expose the company to regional economic and regulatory risks, though no immediate geopolitical threats are flagged in the industry configuration.
Looking ahead, Findex Inc is projected to grow revenue by approximately 23.6% in the next fiscal year, based on analyst estimates of ¥6.25 billion compared to the last actual revenue of ¥6.11 billion. The company's earnings per share (EPS) are also expected to increase, with a mean estimate of ¥54.10 compared to the last actual EPS of ¥50.07. This growth trajectory is supported by the company's strong cash position and lack of debt, which allows for reinvestment and potential expansion.
The risk assessment for Findex Inc indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's dilution potential is also low, as there is no indication of recent or planned share issuances that could dilute existing shareholders. The absence of long-term debt and the high current ratio further mitigate financial risk.
Recent events and filings for Findex Inc do not highlight any significant operational or financial disruptions. The company's latest financial results and analyst estimates suggest stable performance and positive expectations for the near term. No major regulatory changes or market shifts have been reported that would significantly impact the company's operations or valuation.
- Findex Inc has a strong liquidity position with no long-term debt and a current ratio of 5.94.
- The company's profitability metrics, including ROE of 12.23% and ROA of 9.83%, are above industry norms.
- Revenue is concentrated in Japan, with no disclosed international segments, which may pose regional risk.
- Analysts expect a 23.6% revenue growth in the next fiscal year, supported by strong cash reserves.
- The company faces low liquidity and dilution risks, with no immediate filing-based flags detected.
Bull / Bear case
Generated · model-assistedOperating income surged 13.8% year-over-year to JPY 1.73 billion, demonstrating strong top-line momentum and operational efficiency.
The company maintains a zero long-term debt position, eliminating interest expense risks and providing maximum financial flexibility.
Free cash flow grew 19.1% year-over-year to JPY 880.8 million, highlighting robust cash generation capabilities.
Revenue growth decelerated to 4.6% year-over-year in FY2026, suggesting potential saturation or slowing demand in core markets.
Operating income growth slowed to 13.8% in FY2026 compared to higher historical rates, indicating margin expansion challenges.
Net income growth of 8.1% lags behind the 18.6% four-year CAGR, signaling a potential normalization of earnings power.
In focus — financials by report
Revenue ¥1.74B, +13,4% YoY; Operating income +35,3% YoY.
- ▍Revenue ¥1.74B, +13,4% YoY
- ▍Operating income +35,3% YoY
- ▍Net income +22,0% YoY
- ▍Net margin 23.2%
Revenue ¥1.25B, +12,9% YoY; Operating income +29,6% YoY.
- ▍Revenue ¥1.25B, +12,9% YoY
- ▍Operating income +29,6% YoY
- ▍Net income +28,8% YoY
- ▍Net margin 13.5%
Revenue ¥1.17B, +8,6% YoY; Operating income +68,2% YoY.
- ▍Revenue ¥1.17B, +8,6% YoY
- ▍Operating income +68,2% YoY
- ▍Net income +84,0% YoY
- ▍Net margin 9.1%
Revenue ¥1.95B, −8,1% YoY; Operating income −4,5% YoY.
- ▍Revenue ¥1.95B, −8,1% YoY
- ▍Operating income −4,5% YoY
- ▍Net income −10,1% YoY
- ▍Net margin 29.6%
Revenue ¥1.53B; Operating income ¥397.8M.
- ▍Revenue ¥1.53B
- ▍Operating income ¥397.8M
- ▍Net margin 21.6%
Revenue ¥1.10B; Operating income ¥185.3M.
- ▍Revenue ¥1.10B
- ▍Operating income ¥185.3M
- ▍Net margin 11.8%
Revenue ¥1.08B; Operating income ¥78.2M.
- ▍Revenue ¥1.08B
- ▍Operating income ¥78.2M
- ▍Net margin 5.4%
Revenue ¥2.12B; Operating income ¥862.1M.
- ▍Revenue ¥2.12B
- ▍Operating income ¥862.1M
- ▍Net margin 30.3%
Revenue ¥6.11B, +4,6% YoY; Operating income +13,8% YoY.
- ▍Revenue ¥6.11B, +4,6% YoY
- ▍Operating income +13,8% YoY
- ▍Net income +8,1% YoY
- ▍Free cash flow +19,1% YoY
- ▍Net margin 20.6%
Revenue ¥5.84B, +12,5% YoY; Operating income +2,0% YoY.
- ▍Revenue ¥5.84B, +12,5% YoY
- ▍Operating income +2,0% YoY
- ▍Net income +9,8% YoY
- ▍Free cash flow −3,4% YoY
- ▍Net margin 19.9%
Revenue ¥5.19B, +14,3% YoY; Operating income +44,5% YoY.
- ▍Revenue ¥5.19B, +14,3% YoY
- ▍Operating income +44,5% YoY
- ▍Net income +46,5% YoY
- ▍Free cash flow +76,5% YoY
- ▍Net margin 20.4%
Revenue ¥4.54B, −8,6% YoY; Operating income +12,2% YoY.
- ▍Revenue ¥4.54B, −8,6% YoY
- ▍Operating income +12,2% YoY
- ▍Net income +13,6% YoY
- ▍Free cash flow −7,3% YoY
- ▍Net margin 15.9%
Valuation TTM
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 54,10 |
| Revenue | —no estimate | —no estimate | 6,2B JPY |
| Operating income | —no estimate | —no estimate | —no estimate |
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Findex Inc Market data — financials · 2026-05-26
- Findex Inc Market data — analyst estimates · 2026-05-26